Viracta Gross Profit from 2010 to 2024

VIRX Stock

USD 0.16 0.01 6.67%

Viracta Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Viracta Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2005-09-30

Previous Quarter

-110 K

Current Value

-96 K

Quarterly Volatility

455 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Viracta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 1.14. Viracta financial statements analysis is a perfect complement when working with Viracta Therapeutics Valuation or Volatility modules.

Check out the analysis of Viracta Therapeutics Correlation against competitors.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Latest Viracta Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Viracta Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Viracta Therapeutics minus its cost of goods sold. It is profit before Viracta Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Viracta Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viracta Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Viracta Gross Profit Regression Statistics

	Arithmetic Mean	3,085,497
	Geometric Mean	1,246,663
	Coefficient Of Variation	146.63
	Mean Deviation	3,138,449
	Median	2,073,000
	Standard Deviation	4,524,398
	Sample Variance	20.5T
	Range	17M
	R-Value	(0.80)
	Mean Square Error	8.1T
	R-Squared	0.63
	Significance	0.0004
	Slope	(805,163)
	Total Sum of Squares	286.6T

Viracta Gross Profit History

	2024	-467.4 K
	2023	-492 K
	2022	-210 K
	2021	-178 K
	2020	88 K
	2019	2.1 M
	2018	237 K

Other Fundumenentals of Viracta Therapeutics

Gross Profit Margin

Viracta Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Long Term Debt Total	Net Receivables
Total Assets		0.67	-0.06	-0.48	0.65	0.34	0.25	0.13	1.0	-0.2	-0.14	0.3	-0.74	0.15	0.69	0.79	0.62	0.68	0.7	0.36	-0.04
Total Stockholder Equity	0.67		-0.16	-0.38	0.1	0.41	0.13	-0.64	0.66	-0.18	0.16	0.14	-0.65	-0.43	0.66	0.65	0.48	0.53	0.66	0.19	0.05
Current Deferred Revenue	-0.06	-0.16		0.43	-0.1	-0.53	0.4	0.17	-0.04	-0.11	0.1	-0.1	0.29	-0.38	-0.36	-0.44	-0.45	-0.44	-0.12	-0.36	0.29
Net Debt	-0.48	-0.38	0.43		-0.33	-0.49	0.64	0.0	-0.47	0.47	0.12	0.45	0.21	-0.38	-0.25	-0.38	-0.15	-0.21	-0.69	0.24	-0.31
Retained Earnings	0.65	0.1	-0.1	-0.33		0.28	0.03	0.51	0.63	-0.01	-0.51	0.36	-0.5	0.64	0.46	0.57	0.54	0.55	0.26	0.39	-0.28
Accounts Payable	0.34	0.41	-0.53	-0.49	0.28		-0.22	-0.21	0.32	0.03	-0.07	0.25	-0.53	0.06	0.48	0.49	0.44	0.48	0.32	0.33	-0.18
Short Term Investments	0.25	0.13	0.4	0.64	0.03	-0.22		0.09	0.26	0.15	0.02	0.59	-0.3	-0.42	0.15	0.11	0.17	0.19	-0.1	0.49	-0.21
Total Liab	0.13	-0.64	0.17	0.0	0.51	-0.21	0.09		0.15	-0.02	-0.35	0.07	0.12	0.71	-0.2	-0.08	-0.04	-0.04	-0.13	0.09	-0.06
Total Current Assets	1.0	0.66	-0.04	-0.47	0.63	0.32	0.26	0.15		-0.2	-0.12	0.3	-0.74	0.14	0.68	0.78	0.61	0.67	0.7	0.35	-0.03
Short Term Debt	-0.2	-0.18	-0.11	0.47	-0.01	0.03	0.15	-0.02	-0.2		0.19	0.69	-0.31	-0.07	0.41	0.22	0.51	0.42	-0.7	0.55	-0.9
Common Stock	-0.14	0.16	0.1	0.12	-0.51	-0.07	0.02	-0.35	-0.12	0.19		-0.02	0.11	-0.36	-0.07	-0.11	-0.09	-0.1	-0.1	-0.06	0.01
Long Term Debt	0.3	0.14	-0.1	0.45	0.36	0.25	0.59	0.07	0.3	0.69	-0.02		-0.66	-0.07	0.64	0.56	0.75	0.69	-0.28	0.87	-0.78
Capital Surpluse	-0.74	-0.65	0.29	0.21	-0.5	-0.53	-0.3	0.12	-0.74	-0.31	0.11	-0.66		0.04	-0.95	-0.93	-0.91	-0.96	-0.38	-0.77	0.54
Property Plant Equipment	0.15	-0.43	-0.38	-0.38	0.64	0.06	-0.42	0.71	0.14	-0.07	-0.36	-0.07	0.04		-0.01	0.16	0.16	0.15	0.04	0.08	-0.1
Net Tangible Assets	0.69	0.66	-0.36	-0.25	0.46	0.48	0.15	-0.2	0.68	0.41	-0.07	0.64	-0.95	-0.01		0.96	0.96	0.96	0.32	0.68	-0.58
Net Invested Capital	0.79	0.65	-0.44	-0.38	0.57	0.49	0.11	-0.08	0.78	0.22	-0.11	0.56	-0.93	0.16	0.96		0.94	0.96	0.49	0.67	-0.43
Short Long Term Debt	0.62	0.48	-0.45	-0.15	0.54	0.44	0.17	-0.04	0.61	0.51	-0.09	0.75	-0.91	0.16	0.96	0.94		0.98	0.17	0.81	-0.7
Capital Stock	0.68	0.53	-0.44	-0.21	0.55	0.48	0.19	-0.04	0.67	0.42	-0.1	0.69	-0.96	0.15	0.96	0.96	0.98		0.28	0.82	-0.65
Net Working Capital	0.7	0.66	-0.12	-0.69	0.26	0.32	-0.1	-0.13	0.7	-0.7	-0.1	-0.28	-0.38	0.04	0.32	0.49	0.17	0.28		-0.08	0.54
Long Term Debt Total	0.36	0.19	-0.36	0.24	0.39	0.33	0.49	0.09	0.35	0.55	-0.06	0.87	-0.77	0.08	0.68	0.67	0.81	0.82	-0.08		-0.75
Net Receivables	-0.04	0.05	0.29	-0.31	-0.28	-0.18	-0.21	-0.06	-0.03	-0.9	0.01	-0.78	0.54	-0.1	-0.58	-0.43	-0.7	-0.65	0.54	-0.75

Click cells to compare fundamentals

About Viracta Therapeutics Financial Statements

Viracta Therapeutics investors use historical fundamental indicators, such as Viracta Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viracta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-492 K	-467.4 K
Gross Profit Margin	0.84	0.80

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC